The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mark Shlomchik Awarded Inaugural Lupus Insight Prize

Mark Shlomchik Awarded Inaugural Lupus Insight Prize

July 22, 2013 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Mark Shlomchik, MD, PhD, the incoming chair of immunology at the University of Pittsburgh, is the first recipient of the Lupus Insight Prize. The award and $200,000 grant for use in “innovative research” was given by the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute.

You Might Also Like
  • New Lupus Insight Prize Aims to Advance Lupus Research
  • 2018 FNIH Trailblazer Prize for Clinician-Scientists Nomination Deadline: March 30
  • Immunology Research Pioneers Receive Carol Nachman Prize
Also By This Author
  • ACA Upheld: What Does This Mean for Rheumatology?

Dr. Shlomchik will use the grant to continue his research on the connection between the death of neutrophils and lupus. And, frankly, he says the money comes at a good time, as a research proposal to build a new mouse model did not land a National Institutes of Health grant.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Without this award, I would have really had to close down what I consider to be my most promising avenue of lupus research,” Dr. Shlomchik tells The Rheumatologist. “I’m hopeful that this will be a bridge, eventually, to a longer-term project.”

Dr. Shlomchik says he’ll use the Lupus Insight Prize money to develop a new mouse model. A burgeoning technique that can pre-engineer an autoimmune-prone, genetic background could yield experiment-ready mice in six months. A more traditional approach could take nearly two years to have mice ready for experiments. Thanks to the size of the grant, he says he might even have enough money to do both.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Though the time frame for results may sound long to some, Dr. Shlomchik adds that he is accustomed to looking at long-term benefits in a field that focuses on a chronic disease.

“We all are eager to get to the answers as quickly as we can, but ultimately, by understanding the mechanisms of lupus, we can hopefully use this as an approach for either diagnosis or therapy as well,” he says. “That’s a much longer time horizon, but this is the way that treatments are determined. You have to understand why it goes wrong.”


Richard Quinn is a freelance writer in New Jersey.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Professional Topics Tagged With: Lupus, mouse model, neutrophils

You Might Also Like:
  • New Lupus Insight Prize Aims to Advance Lupus Research
  • 2018 FNIH Trailblazer Prize for Clinician-Scientists Nomination Deadline: March 30
  • Immunology Research Pioneers Receive Carol Nachman Prize
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)